Inebilizumab for Children with Neuromyelitis Optica Spectrum Disorder

We are studying how the medication inebilizumab affects children and adolescents with NMOSD. The trial will help us learn about its safety and how it impacts their health and daily life.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Inebilizumab
Inebilizumab reduces B cells to help prevent relapses in neuromyelitis optica spectrum disorder, a condition affecting the optic nerves and spinal cord.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Assistance Publique Hopitaux De Paris
Pediatric Neurology Department
Croulebarbe, France
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Neurologie
Rotterdam, Netherlands
Uniwersyteckie Centrum Kliniczne
Klinika Neurologii Rozwojowej
Wrzeszcz Dolny, Poland

Sponsor: Horizon Therapeutics Ireland Designated Activity Company
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.